Literature DB >> 33488032

The Impact of COVID-19 on Elective Cardiovascular Procedures in Taiwan - A Single-Center Experience.

Chia-Te Liao1,2, Zhih-Cherng Chen1, Wei-Ting Chang1,3,4.   

Abstract

COVID-19 has reached a pandemic level and affected both individual's health and global healthcare systems. Although Taiwan has encountered a less severe COVID-19 pandemic than many other countries, it has impacted the workflow of all cardiovascular examinations and procedures. Compared to before January 21st, 2020 (the date of the first confirmed COVID-19 in Taiwan), the number of patients who have received echocardiography and cardiac catheterization has since fallen. However, the number of percutaneous coronary interventions being performed has remained at the usual level. Based on our experience, we suggest that healthcare providers in Taiwan should carefully evaluate the urgency of cardiovascular procedures and deferred non-emergent procedures. Given that the pandemic has not yet plateaued, we should remain prepared for future challenges to maintain our medical service.

Entities:  

Keywords:  COVID-19; Elective cardiovascular procedures; Workflow

Year:  2021        PMID: 33488032      PMCID: PMC7814330          DOI: 10.6515/ACS.202101_37(1).20200920A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  6 in total

1.  Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing.

Authors:  C Jason Wang; Chun Y Ng; Robert H Brook
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

2.  No Reduction of ST-segment Elevation Myocardial Infarction Admission in Taiwan During Coronavirus Pandemic.

Authors:  Yi-Heng Li; Wei-Chun Huang; Juey-Jen Hwang
Journal:  Am J Cardiol       Date:  2020-06-27       Impact factor: 2.778

3.  Ramping Up the Delivery of Cardiac Surgery During the COVID-19 Pandemic: A Guidance Statement From the Canadian Society of Cardiac Surgeons.

Authors:  Ansar Hassan; Rakesh C Arora; Sylvain A Lother; Corey Adams; Denis Bouchard; Richard Cook; Derek Gunning; Yoan Lamarche; Tarek Malas; Michael Moon; Maral Ouzounian; Vivek Rao; Fraser Rubens; Philippe Tremblay; Richard Whitlock; Emmanuel Moss; Jean-François Légaré
Journal:  Can J Cardiol       Date:  2020-04-29       Impact factor: 5.223

4.  Initial rapid and proactive response for the COVID-19 outbreak - Taiwan's experience.

Authors:  Hao-Yuan Cheng; Shu-Ying Li; Chin-Hui Yang
Journal:  J Formos Med Assoc       Date:  2020-03-25       Impact factor: 3.282

5.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.

Authors:  Wei-Jie Guan; Wen-Hua Liang; Yi Zhao; Heng-Rui Liang; Zi-Sheng Chen; Yi-Min Li; Xiao-Qing Liu; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Chun-Quan Ou; Li Li; Ping-Yan Chen; Ling Sang; Wei Wang; Jian-Fu Li; Cai-Chen Li; Li-Min Ou; Bo Cheng; Shan Xiong; Zheng-Yi Ni; Jie Xiang; Yu Hu; Lei Liu; Hong Shan; Chun-Liang Lei; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Lin-Ling Cheng; Feng Ye; Shi-Yue Li; Jin-Ping Zheng; Nuo-Fu Zhang; Nan-Shan Zhong; Jian-Xing He
Journal:  Eur Respir J       Date:  2020-05-14       Impact factor: 16.671

6.  Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association.

Authors:  Dhanunjaya R Lakkireddy; Mina K Chung; Rakesh Gopinathannair; Kristen K Patton; Ty J Gluckman; Mohit Turagam; Jim W Cheung; Parin Patel; Juan Sotomonte; Rachel Lampert; Janet K Han; Bharath Rajagopalan; Lee Eckhardt; Jose Joglar; Kristin E Sandau; Brian Olshansky; Elaine Wan; Peter A Noseworthy; Miguel Leal; Elizabeth Kaufman; Alejandra Gutierrez; Joseph E Marine; Paul J Wang; Andrea M Russo
Journal:  Heart Rhythm       Date:  2020-04-01       Impact factor: 6.343

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.